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The aim of the study was to evaluate changes in the opioid receptor binding (mu, delta and
kappa) in the hypothalamus, anterior pituitary and adrenal cortex (HPA) of lambs treated in
vivo with corticotrophin releasing hormone (CRH), naltrexone, an opioid receptor antagonist
(NAL), and dexamethasone, a potent cortisol analog (DEX). Experiment was carried out on 3
months old female lambs of polish mountain strain. Lambs received a single i.v. injection of
NaCl (control), CRH (alone or in combination with naltrexone), naltrexone or
dexamethasone. One hour later animals were decapitated under anaesthesia, tissues were
dissected out and receptor binding assays were performed with radioligands for each type of
opioid receptors – 3H-DAGO, 3H-DPDPE and 3H-EKC for mu, delta and kappa receptor,
respectively. Coexistence of specific binding sites for each type of opioid receptor was
demonstrated in all levels of HPA axis of control lambs, however their distribution was
uneven. Acute treatment with CRH, DEX and NAL caused downregulation or upregulation of
mu, delta, kappa receptor binding in each level of HPA axis. CRH effects on mu, delta and
kappa opioid receptor binding varied within the HPA axis and were modulated by
naltrexone. Treatment with naltrexone increased in vitro mu, delta and kappa receptor
binding in most tested structures except delta receptor binding in adrenal (decrease by 52%)
and kappa receptor binding in pituitary (decrease by 41%). Dexamethasone significantly
decreased the mu, delta and kappa opioid receptor binding in adrenal cortex but differentially
affected opioid receptor binding in hypothalamus and pituitary. It seems probable that
endogenous opioid peptides acting through mu, delta and kappa receptors interact with the
hormones released from the hypothalamic-pituitary-adrenal axis in physiological and
pathophysiological situations.
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Endogenous opioid peptides and their receptors
are broadly expressed throughout peripheral and
central nervous systems and have been investi-
gated for several decades. The opioid system plays
a central role in nociception and analgesia, and
also regulates numerous physiological functions
as respiration, gastrointestinal transit and response
to stress, as well as endocrine and immune functions
(BODNAR 2013). Since 1992 when the first opioid
receptor gene was identified by expression cloning
several homologous genes were discovered. The
opioid receptor gene family consists of three mem-
bersencodingmu(MOR,Oprm1),delta (DOR,Oprd1),
kappa (KOR, Oprk1) receptors and recently the
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nonopioid orphaninFQ/nociceptin (NOR, Oprl1)
receptor was included. These receptors are mem-
brane receptors with a seven-transmembrane to-
pology and belong to the large G protein-coupled
receptor superfamily (BODNAR 2013).
The first endogenous ligands for delta receptors
characterized by HUGHES et al. (1975) were two
pentapeptides, Met- and Leu-enkephalin. Since
then, many peptides forming the opioid peptide
families of enkephalins, dynorphins, and â-endo-
rphin were discovered. Opioid peptides are syn-
thesized as large protein precursors named as
preproenkephalin (PENK), preprodynorphin (PDYN),
and proopiomelanocortin (POMC), respectively.
However, in spite of many research on the opioid
receptors cloning, distribution in the nervous sys-
tem and peripheral tissues, only then in 2012 four
papers reported crystal structures that provide the
first direct evidence for the binding mode of
opioids to their receptors (GRANIER et al. 2012;
MANGLIK et al. 2012; THOMPSON et al. 2012; WU
et al. 2012).
Maintenance of homeostasis in the presence of
variety of challenges requires activation of a com-
plex responses of the endocrine, nervous, and im-
mune systems, known as the stress response.
Disturbance of the stress response has been linked
to a wide array of pathologies mainly autoimmune
disease, hypertension, affective disorders, and ma-
jor depression (KOOB 1999; BODNAR 2013).
Opioid peptides are also involved into mecha-
nism activated during stress response, such as the
regulation of the hypothalamic-pituitary-adrenal
axis (HPA) activity. Opioid-containing neurons
(mainly endorphins and enkephalins) innervate
the paraventricular nucleus, the median eminence
and affected adrenocorticotrophin hormone
(ACTH)-controlling neurons (SMITH & VALE 2006;
LEMERRER et al. 2009; VANVEER et al. 2012).
Dynorphin, an endogenous ligand for kappa recep-
tors, as well as endorphin (mu receptor ligand) and
enkephalins (delta receptor agonists) are localized
with corticotrophin releasing hormone (CRH) in
hypothalamus and probably are simultaneously se-
creted to modulate ACTH release (BRUCHAS et al.
2009; LEMOS et al. 2012; FUNK et al. 2014). Our
previous experiments showed that emotional
stress evoked by isolation of animals from the
herd, without acoustic and visual contact, signifi-
cantly changed the concentration of opioids in the
all levels of hypothalamic-pituitary-adrenal axis
and decreased delta receptor binding in the hypo-
thalamus (PIERZCHA£A-KOZIEC et al. 2006). Si-
multaneously, increased plasma levels of ACTH
and cortisol were observed what might suggest an
interaction of the opioid system and stress hor-
mones. Sheep are useful animal model for the
studying the effects of emotional stress due to their
vulnerability to such stressors, however, no com-
plex analysis of opioid receptor binding in stressed
sheep has been performed so far. In order to mini-
mize the side effects of environmental stress fac-
tors (induced for example by lamb isolation) direct
treatment with known concentrations of HPA axis
hormones is much suitable and may give much
faster response of endogenous opioid peptides and
their receptors.
Thus, the aim of the study was to evaluate mu-,
delta- and kappa-opioid receptor binding in the hy-
pothalamus, anterior pituitary and adrenal cortex
of lambs treated in vivo with corticotrophin releas-
ing hormone, dexamethasone, a potent cortisol




Experiment was carried out on thirty 3 months
old lambs (females) of polish mountain breed (Pol-
ish Mountain Sheep). Animals were housed in in-
dividual cages under constant conditions of
temperature (18ºC), humidity and 12L:12D cycle
(light on 7a.m. to 7 p.m.) for one week before the
study. Animals had free access to water and feed.
The protocol was approved by the First Local
Ethical Committee on Animal Testing in Kraków
(64/OP/2005/I LKE).
Lambs were divided into 5 groups (n=6) and in-
jected intravenously at 9 a.m. with either 0.9%
NaCl (control), or naltrexone hydrochloride (3
mg/kg b.w. SIGMA), corticotrophin releasing
hormone (CRH, rat, 1 Fg/kg b.w. SIGMA), CRH
with naltrexone and dexamethasone (Dexaven, 0.1
mg/kg b.w. PHARMASWISS Czech Republic).
One hour later, lambs were decapitated under an-
aesthesia and fragments of hypothalamus, anterior
pituitary and adrenal cortex were dissected out.
Tissues were immediately frozen on dry ice and
stored at -70ºC until receptor binding assays were
performed.
Receptor binding assays
Receptor binding assays were performed accord-
ing to procedures reported elsewhere (BELCHEVA
et al. 1994; HYTREK et al. 1996) with some modi-
fication. According to results of pilot study estab-
lishing Kd and Bmax, optimal levels of specific
ligands for mu, kappa and delta receptors were
chosen (data not shown). Briefly, the dissected tis-
sues were homogenized in ice-cold buffer 50 mM
Tris-HCl, pH=7.4. The homogenate was centri-
fuged at 20000xg for 15 min at 4°C and cell mem-
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brane preparations (1 ml, 1 mg of protein, in
triplicate) were incubated at 30ºC for 30 min with
200 Fl of 26.00 nM of 3H-DAGO (D-Ala2, Me-
Phe4, Gly(ol)5 enkephalin for mu receptor), 6.80
nM of 3H-DPDPE (D-Ala2-,N-Me-Phe4,Gly-ol for
delta receptor subtype) and 59.18 nM of 3H-EKC
(ethylketocyclazocine for kappa receptor). Radio-
ligands were purchased from Amersham Interna-
tional (3H-DAGO, 3H-DPDPE) and from New
England Nuclear (3H-EKC). The pilot study gave
the reason to unify the concentrations of unlabeled
ligands used for the nonspecific binding for all
three types of opioid receptors (unpublished data).
Nonspecific binding was obtained with 10 FM of
unlabeled ligands: morphine for mu, Met-enkephalin
for delta and Leu-enkephalin-Arg for kappa recep-
tors (Sigma) incubated together with the radio-
ligands. Free ligand was separated from membrane
bound radioligand by filtration under reduced
pressure through GF/B Whatman glass filters in
the room temperature for 1 min. Protein concentra-
tion was determined by the BCA method (OLSON
& MARKWELL 2007).
Statistical analysis
Data were analyzed by one-way analysis of vari-
ance (ANOVA) and Student-Newman-Keul’s
post hoc test.
Results
Mu receptor binding (Fig. 1).
The mu receptor binding of 3H-DAGO in control
animals was the lowest in pituitary – 2.30±0.21
fmol/mg protein compared to 5.11±0.31 fmol/mg
protein in hypothalamus and 10.02±0.92 fmol/mg
protein in adrenal cortex. CRH increased the re-
ceptor binding in hypothalamus by 49% (from
5.11±0.31 to 7.60±0.62 fmol/mg protein, P<0.05)
and downregulated the binding by 48% in pituitary
(decrease from 2.30±0.21 to 1.18±0.10 fmol/mg
protein, P<0.05) and by 44% in adrenal cortex (de-
crease from 10.02±0.92 to 5.60±0.47 fmol/mg
protein, P<0.05). Naltrexone potentiated the effect
of CRH in hypothalamus what resulted in signifi-
cant increase of mu receptor binding by 131%
compared to control value (increase to the level of
11.80±1.01 fmol/mg protein, P<0.05). Opioid an-
tagonist did not change the effect of CRH in pitui-
tary MOR binding and only slightly increased by
19% the mu receptor binding in the adrenal cortex
(P<0.05). Treatment with naltrexone increased the
mu receptor binding in hypothalamus by 191%, in
anterior pituitary by 136% and in adrenal cortex by
91% (P<0.05). Injection of dexamethasone sig-
nificantly increased the mu receptor binding in hy-
pothalamus (by 172%), pituitary (by 95%) but
decreased the binding by 51% in adrenal cortex
(P<0.01).
Delta receptor binding (Fig. 2).
The delta receptor binding of 3H-DPDPE in con-
trol animals ranged from 55.31±5.18 in hypothala-
mus to 45.44±4.17 in anterior pituitary and to
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Fig. 1. 3H-DAGO binding to cell membrane preparations
from lamb hypothalamus, anterior pituitary and adrenal
cortex (fmol/mg of proteins). C-control (saline injected),
CRH-(corticotrophin releasing hormone injected),
CRH+NAL-(corticotrophin releasing hormone plus naltrexone
injected), NAL-(naltrexone injected), DEX-dexamethasone-treated
animals. Each bar represents the mean of six animals±SEM.
Means with superscripts a,b,c,d,e differ significantly at the
P<0.05.
44.03±3.91 fmol/mg protein in adrenal cortex.
Acute treatment with CRH alone or in combina-
tion with naltrexone as well as injection with dex-
amethasone significantly downregulated the
receptor binding (20-90%) in all tested tissues
(P<0.05). The strongest effect of CRH on the delta
receptor binding was seen in hypothalamus (de-
crease by 72%) compare to anterior pituitary and
adrenal cortex (receptor binding fall by 46%,
P<0.05). Naltrexone potentiated that inhibiting ef-
fect of CRH on the receptor binding only in the ad-
renal (by 35%). A single injection of naltrexone
upregulated the delta receptor binding in the hypo-
thalamus (increase from 55.31±5.81 to 90.33±10.21
fmol/mg protein, 67%, P<0.05) and caused mild
increase in anterior pituitary (by 22%, P<0.05). In
contrast, injection of antagonist resulted in signifi-
cant (by 50%) reduction of delta receptor binding
in adrenal cortex from 44.03±3.92 to 22.11±2.32
fmol/mg protein (P<0.05).
Kappa receptor binding (Fig. 3).
The kappa receptor binding of 3H-EKC varied
from 18.82±1.53 fmol/mg protein in hypothala-
mus to 75.04±5.36 in anterior pituitary and to
Fig. 2. 3H-DPDPE binding to cell membrane preparations
from lamb hypothalamus, anterior pituitary and adrenal
cortex (fmol/mg of proteins). C-control (saline injected),
CRH-(corticotrophin releasing hormone injected),
CRH+NAL-(corticotrophin releasing hormone plus
naltrexone injected), NAL-(naltrexone injected),
DEX-dexamethasone-treated animals. Each bar represents
the mean of six animals±SEM. Means with superscripts
a,b,c,d differ significantly at the P<0.05.
Fig. 3. 3H-EKC binding to cell membrane preparations from
lamb hypothalamus, anterior pituitary and adrenal cortex
(fmol/mg of proteins). C-control (saline injected),
CRH-(corticotrophin releasing hormone injected),
CRH+NAL-(corticotrophin releasing hormone plus naltrexone
injected), NAL-(naltrexone injected), DEX-dexamethasone-treated
animals. Each bar represents the mean of six animals±SEM.
Means with superscripts a,b,c,d,e differ significantly at the
P<0.05.
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390.12±41.21fmol/mg protein in adrenal cortex of
control lambs (P<0.05). Corticotrophin releasing
hormone significantly increased the kappa recep-
tor binding in every level of HPA axis by 2-4 folds
(P<0.05). Naltrexone in combination with CRH
reversed the stimulating effect of CRH in anterior
pituitary (completely) and adrenal cortex
(slightly). A single injection of naltrexone signifi-
cantly increased the kappa receptor binding in hy-
pothalamus and adrenal, and downregulated in
pituitary (P<0.05). Dexamethasone increased the
kappa receptor binding in hypothalamus (by 43%,
P<0.05) but decreased in pituitary (by 20%,
P<0.05) and in adrenal cortex (by 67%, P<0.05).
Interestingly, kappa receptor binding was much
higher in the adrenal cortex than in hypothalamus
and anterior pituitary, and varied from
390.12±41.21 in control lambs to 1514.33±99.23
fmol/mg protein in adrenal from CRH treated ani-
mals, and to 780.45±101.27 fmol/mg protein in
adrenal taken from naltrexone injected lambs.
Discussion
The distribution of opioid binding sites in the
brain was analyzed by different methods in rats
(UNDERWALD et al. 1998; WAND et al. 2012),
mice (BRADY et al. 1999), guinea pig (LEWIS et al.
1985; FOOTE & MAURER 1986). In our study, the
coexistence of specific binding sites for mu, delta
and kappa opioid receptors was demonstrated in
each level of hypothalamic-pituitary-adrenal axis
in control lambs, however their distribution was
uneven. The 3H-DPDPE binding to DOR was
about 20% higher in hypothalamus than in pitui-
tary or adrenals. Unexpectedly, 3H-EKC binding
to kappa sites in the adrenal cortex was 18 and 5
fold higher than in hypothalamus and in pituitary,
respectively. An unequal distribution of the opioid
receptors and their mRNA’s was also found in the
rat study (GEORGE et al. 1994; MANSOUR et al.
1994; GERRA et al. 2006). They showed the high-
est expression of mu receptor mRNA in several
thalamic nuclei together with increased binding
properties of that receptor compared to pituitary.
In contrast, expression of delta receptor mRNA
and the agonist binding were much lower in the hy-
pothalamus. Distribution of kappa receptor
mRNA in hypothalamus was quite similar to that
seen for mu receptor, however the agonist binding
was found only in several hypothalamic nuclei.
Similarly to the varied radioligand receptors
binding in control lambs, we found inconsistent re-
action to the i.v. of drug injection. Generally, corti-
cotrophin releasing hormone increased the kappa
agonist binding and decreased delta agonist bind-
ing in all tested tissues. CRH also increased the
MOR binding in hypothalamus but caused signifi-
cant fall of the binding in anterior pituitary and ad-
renal cortex. It seems probable that CRH
stimulated endogenous enkephalins release which
were bound to delta receptors not only in hypo-
thalamus but also in the pituitary and adrenal cor-
tex, where the 3H-DPDPE binding in vitro was
much lower than in control animals. Agonist acti-
vation of the delta opioid receptor is able to initiate
G-protein-dependent and independent signaling
pathway. It was found that agonist induced activa-
tion of the delta opioid receptor leads to receptor
desensitization and finally to internalization
(PRADHAN et al. 2009).
The presence of kappa opioid receptor in the
lamb hypothalamus was proved in several experi-
ments what may suggest an important role of
dynorphin in the modulation of hypothalamic neu-
ropeptides secretion (DEPAOLI et al. 1994; FUNK
et al. 2014). In the present experiment, kappa re-
ceptor binding in the hypothalamus was much
lower than in pituitary and adrenal but every treat-
ment evoked significant increase of KOR in this
structure. Similar results were showed by BOY-
ADJIEVA et al. (2004) in experiment testing the
opioid effects on immune system at the brain level.
In contrast, the stimulating effect of acute CRH in-
jection on the 3H-EKC binding was much more po-
tentiated in the anterior pituitary and adrenal
cortex compared to the reaction seen in the hypo-
thalamus. It seems probable, that increased level
of CRH caused upregulation of kappa receptors
and/or inhibition of dynorphin release from the
nerves endings. This effect was similar to that seen
after naltrexone, an opioid receptors antagonist,
treatment. Previously, it was found that exercise
stress (long walking of sheep) and restraint stress
in hens which were accompanied by increased
level of CRH significantly lowered the plasma
level of dynorphin-like peptide (PIERZCHALA &
PRZEWLOCKI1989;PIERZCHALA-KOZIECetal.1999).
Previous studies in our laboratory and elsewhere
have established that the stress-related corticotro-
phin releasing hormone is a critical mediator of re-
sponses to different stressors including isolation,
restraint, footshock and yohimbine (PIERZCHA-
LA-KOZIEC et al. 1999; LE et al. 2000; MARINELLI
et al. 2007). Recent work has begun to determine
how CRH may interact with other neurotransmit-
ters in stress-related behaviors such as anxiety and
place aversion. Results from MCLAUGHLIN et al.
(2006) showed that one of the neurotransmitter,
the endogenous opioid dynorphin and its receptor
(kappa opioid receptor) are involved in responses
to stress. LAND et al. (2008) prooved that dynor-
phin is involved in motivation to seek alcohol and
other drugs (WALKER et al. 2011; SCHANK et al.
2012). Although KOR and CRH receptors have
been shown to interact in stress-related behaviors
(LAND et al. 2008), little is known about how they
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may interact in stress-induced reinstatement of
mood and emotional disturbances.
The mu receptor binding performed with3H-DAGO in in vitro conditions was increased in
hypothalamus and anterior pituitary of lambs
treated by naltrexone what might indicated that
this antagonist caused MOR desensitization. LAM
et al. (2011) suggested that constitutive activity at
the mu receptor can be reversed by naltrexone
which is also proposed as an inverse agonist. How-
ever, in the present study, in hypothalamus and in
adrenal cortex the join effect of CRH and naltrex-
one caused an increase of the mu receptor binding
compared to CRH-alone treated lambs. In both tis-
sues the level of agonist binding was significantly
higher than in CRH-treated group.
Endogenous opioidergic systems, especially
pro-opiomelanocortin (POMC)-derived beta-
endorphin, exert inhibitory effects on the hypo-
thalamic-pituitary-adrenal (HPA) axis. Beta-endorphin
immunoreactive fibers and corticotrophin-releasing
hormone perikarya are colocalized in the paraven-
tricular nucleus (PVN) of the hypothalamus.To
exert a tonic inhibition on CRH neuronal activity,
it is suggested that beta-endorphin acts primarily
at the mu opioid receptor. It might be also postu-
lated that CRH inhibited the mu receptor activity
through paracrine mode.
Glucocorticoid treatment and stress have been
reported to augment the reinforcing and locomotor-
activating properties of opiates, cocaine and am-
phetamine (KALIVAS & STEWART 1991). Opiate
like peptides such as endorphins, enkephalins and
dynorphins were changed concomitantly with glu-
cocorticoids during stress in rats (PIERZCHALA &
VAN LOON 1990) and lambs (PIERZCHALA-KO-
ZIEC et al. 2006). Intravenous injection of dex-
amethasone increased the mu receptor binding in
hypothalamus and pituitary, what might be the ef-
fect of proopiomelanocortin (precursor of ACTH
and beta-endorphin) synthesis and/or inhibition of
opioid secretion. On the other hand, injection of
dexamethasone resulted in lower mu, delta and
kappa tritiated agonists receptor binding in lamb
adrenal cortex. Thus, it appears that in peripheral
level of HPA axis, dexamethasone caused down-
regulation of all three classes of opioid receptors.
The present data confirm the previous findings
(PIERZCHALA-KOZIEC et al. 2000) that three ma-
jor classes of receptors and their activity are dis-
tinct from each other. Thus, it seems probable that
during stress reaction, when CRH, ACTH and glu-
cocorticoids are elevated, endogenous opioid pep-
tides modulated the regulatory mechanism by
different separable binding to specific receptors at
the central and peripheral levels. Our results ob-
served after i.v. injection of CRH and DEX are in
agreement with those of PRADHAN et al. (2012)
and also indicated that there is independent modu-
lation of the hypothalamic-pituitary-adrenal axis
by endogenous opioid peptides at F-, ä- and
ê-opioid receptors.
In contrast, recent studies on mice demonstrated
the potential heteromeric interaction between
delta and mu receptors in vivo through the use of
monoclonal antibodies, where chronic morphine
exposure upregulated their expression (GUPTA et al.
2010; HE et al. 2011). However, in light of these
findings, mu and delta heteromers might be prom-
ising and desirable targets mainly for the pharma-
cological management of chronic or neuropathic
pain (ROZENFELD & DEVI 2010) and treatment of
addiction disorders (STOCKTON & DEVI 2012).
In conclusion, corticotrophin releasing hormone
effects on mu, delta and kappa opioid receptors
binding appeared to be dependent on the level of
HPA axis and were modulated by naltrexone. Dex-
amethasone, a potent cortisol analog decreased the
mu, delta and kappa opioid receptor binding in ad-
renal cortex. It seems probably that opioid recep-
tors play differential roles in modulating neuronal
activity across different brain and peripheral re-
gions.
In particular, the evaluation of opioid interac-
tion with the hormones of HPA axis may provide
new elements for the development of mu, delta or
kappa receptors-based therapeutic strategies.
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